2024
DOI: 10.1002/nbm.5095
|View full text |Cite
|
Sign up to set email alerts
|

Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous

Gülnur Ungan,
Albert Pons‐Escoda,
Daniel Ulinic
et al.

Abstract: The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow‐up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast‐enhancing regions may appear that can correspond to true progression or pseudoprogression. We retrospectively evaluated 31 consecutive patients at the first follow‐up after concomitant treatment to check whether the metabolic pattern assesse… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 57 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?